A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Journal of the American Medical Association (JAMA)

• Publication date

  1992-11-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/JAMA.1992.03490180055026PMID 1404819
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tacrine in Alzheimer's disease

  1992cited by this paper
• Effect of tetrahydroaminoacridine on cognition, function and behaviour in Alzheimer's disease.

  1991cited by this paper
• Neuropathologic and neurochemical correlates of psychosis in primary dementia.

  1991cited by this paper
• Loss of dopamine uptake sites labeled with [3H]GBR-12935 in Alzheimer's disease.

  1990cited by this paper
• Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.

  1990cited by this paper
• Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study.

  1990cited by this paper
• Survival of outpatients with Alzheimer-type dementia.

  1990cited by this paper
• Substance P and somatostatin coexist within neuritic plaques: implications for the pathogenesis of Alzheimer's disease.

  1989cited by this paper
• Measurement of quality-of-life changes in patients with Alzheimer's disease.

  1989cited by this paper
• Tacrine in Alzheimer's disease.

  1989cited by this paper
• Present progress and future development in the therapy for Alzheimer's disease.

  1989cited by this paper
• Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report.

  1988cited by this paper
• Induction of depression with oxotremorine in patients with Alzheimer's disease.

  1987cited by this paper
• Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.

  1986cited by this paper
• Alzheimer's disease.

  1986cited by this paper
• Severe dementia. Prevalence and clinical features in a biracial US population.

  1985cited by this paper
• A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease.

  1985cited by this paper
• Oral physostigmine treatment of patients with Alzheimer's disease.

  1985cited by this paper
• Prevalence of severe dementia in Finland

  1985cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• A new rating scale for Alzheimer's disease.

  1984cited by this paper
• The Global Deterioration Scale for assessment of primary degenerative dementia.

  1982cited by this paper
• Modest facilitation on memory in dementia with combined lecithin and anticholinerestase treatment.

  1982cited by this paper
• Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine.

  1982cited by this paper
• Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients.

  1981cited by this paper
• Pathological verification of ischemic score in differentiation of dementias

  1980cited by this paper
• Dementia: an approaching epidemic

  1979cited by this paper
• Selective loss of central cholinergic neurons in Alzheimer's disease.

  1976cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper

• Theories of Alzheimer’s disease: Amyloid hypothesis, blood-brain barrier hypothesis and cholinergic hypothesis

  2024cites this paper
• Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer’s disease

  2022cites this paper
• An In Vivo Definition of Brain Histamine Dynamics Reveals Critical Neuromodulatory Roles for This Elusive Messenger

  2022cites this paper
• WBI Studies Repository WBI Studies Clinical trials and late-stage drug development in Alzheimer’s Clinical trials and late-stage drug development in Alzheimer’s disease: An appraisal from 1984 to 2014 disease: An appraisal from 1984 to 2014

  2022cites this paper
• Medicinal plants: A promising breakthrough in the management of Alzheimer's disease progression compared to than NSAID

  2022cites this paper
• The Therapeutic Effects of Seven Lycopodium Compounds on Cell Models of Alzheimer’s Disease

  2022cites this paper
• Pharmacological Management of Dementia—An Overview

  2021cites this paper
• The design of fluoroquinolone-based cholinesterase inhibitors: Synthesis, biological evaluation and in silico docking studies

  2021cites this paper
• New approaches to symptomatic treatments for Alzheimer’s disease

  2021cites this paper
• Advances on plant extracts and phytocompounds with acetylcholinesterase inhibition activity for possible treatment of Alzheimer's disease

  2021cites this paper
• An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease

  2020cites this paper
• Alzheimer's Disease Therapeutic Approaches.

  2020cites this paper
• Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors

  2020cites this paper
• One‐Pot Mannich, Aza‐Wittig and Dehydrofluorinative Aromatization Reactions for Direct Synthesis of 2,3‐Disubstituted 4‐Aminoquinolines

  2020cites this paper
• Therapeutic Evaluation of Herbs With Enzyme Inhibition Studies

  2019cites this paper
• The Role of Biomarkers in Alzheimer's Disease Drug Development.

  2019cites this paper
• Alzheimer’s Disease Pharmacotherapy in Relation to Cholinergic System Involvement

  2019cites this paper
• Cholinesterase inhibitors as Alzheimer's therapeutics

  2019cites this paper
• Substrates of Human CYP2D6

  2018cites this paper
• Preclinical to Human Translational Pharmacology of the Novel M1 Positive Allosteric Modulator MK-7622

  2018cites this paper
• Protective effects of cultured and fermented ginseng extracts against scopolamine-induced memory loss in a mouse model

  2018cites this paper
• Scoring systems for the Clock Drawing Test: A historical review

  2017cites this paper
• Small molecular floribundiquinone B derived from medicinal plants inhibits acetylcholinesterase activity

  2017cites this paper
• Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial

  2017cites this paper
• Pharmacokinetics and Metabolism of Acridine Drugs

  2017cites this paper
• List of excluded studies and reasons for exclusion

  2017cites this paper
• Multitarget Tacrine Hybrids with Neuroprotective Properties to Confront Alzheimer's Disease.

  2017cites this paper
• Biomedical Applications of Acridines

  2017cites this paper
• Quantitative sodium MR imaging: A review of its evolving role in medicine

  2016influential citation
• Function and clinical meaningfulness of treatments for mild Alzheimer's disease

  2016cites this paper
• Predictors of Response to Cholinesterase Inhibitors Treatment of Alzheimer’s Disease: Date Mining from the TREDEM Registry

  2016cites this paper
• Pharmacological management of anticholinergic delirium - theory, evidence and practice.

  2016cites this paper
• Symptomatic Cognitive Enhancing Agents

  2016cites this paper
• Extended-Release Physostigmine in Alzheimer Disease

  2016cites this paper
• The acute hepatotoxicity of tacrine explained by 1H NMR based metabolomic profiling

  2015cites this paper
• Preparation of 7-Methoxy Tacrine Dimer Analogs and Their In vitro/In silico Evaluation as Potential Cholinesterase Inhibitors

  2015cites this paper
• Alzheimer's disease clinical trials: past failures and future opportunities

  2015cites this paper
• Tacrine, an oral acetylcholinesterase inhibitor, induced hepatic oxidative damage, which was blocked by liquiritigenin through GSK3-beta inhibition.

  2015cites this paper
• Prenatal antidepressant exposure associated with CYP2E1 DNA methylation change in neonates

  2015cites this paper
• Acetylcholinesterase inhibition activity of some quinolinyl substituted triazolothiadiazole derivatives

  2015cites this paper
• Avaliação da atividade biológica e teor em fenóis de diferentes extratos de palmeira anã (Chamaerops Humilis L.)

  2015cites this paper
• Effect of Donepezil, an Acetylcholinesterase Inhibitor, on Spatial Learning and Memory in Mice

  2015cites this paper
• Clinical trials and late‐stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

  2014cites this paper
• Tacrine sinusoidal uptake and biliary excretion in sandwich-cultured primary rat hepatocytes.

  2014cites this paper
• Pharmacological properties of AC-3933, a novel benzodiazepine receptor partial inverse agonist.

  2014cites this paper
• Nitrate Chimeras: A New Class of Disease Modifying Agents for the Treatment of Alzheimer's Disease

  2014cites this paper
• Neuroplasticity, neurotransmitters and new directions for treatment of anomia in Alzheimer disease

  2014cites this paper
• A resurrection of 7-MEOTA: a comparison with tacrine.

  2013cites this paper
• Diagnosis and management of Alzheimer's disease: past, present and future ethical issues.

  2013cites this paper
• Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer's disease patients.

  2013cites this paper
• INHIBITION OF ACETYLCHOLINESTERASE ACTIVITY BY HIDROALCOHOLIC EXTRACT AND THEIR FRACTIONS OF BOUVARDIA TERNIFOLIA (CAV.) SHCLTDL (RUBIACEAE).

  2012cites this paper
• Cholinesterase Inhibitors for Alzheimer’s Disease

  2012cites this paper
• Synthesis, Acetylcholinesterase and Alkaline Phosphatase Inhibition of Some New 1,2,4-Triazole and 1,3,4-Thiadiazole Derivatives

  2012cites this paper
• Synthesis, Urease and Acetylcholine Esterase Inhibition Activities of Some 1,4-Disubstituted Thiosemicarbazides and their 2,5-Disubstituted Thiadiazoles

  2012cites this paper
• Antipsychotics Versus Cholinesterase Inhibitors for the Treatment of Psychosis in Alzheimer's : A Critical Review

  2012cites this paper
• Synthesis and Biological Activities of Some New 3,6-Disubstituted 1,2,4-Triazolo(3,4-b)1,3,4-thiadiazole Derivatives

  2012cites this paper
• Reviewing the role of donepezil in the treatment of Alzheimer's disease.

  2012cites this paper
• Structure-based drug discovery of ApoE4 inhibitors from the plant compounds

  2012cites this paper
• The Cost of Alzheimer’s Disease

  2012cites this paper
• Carbamate derivatives of indolines as cholinesterase inhibitors and antioxidants for the treatment of Alzheimer's disease.

  2012cites this paper
• Synthesis and in silico evaluation of 1N-methyl-1S-methyl-2-nitroethylene (NMSM) derivatives against Alzheimer disease: to understand their interacting mechanism with acetylcholinesterase

  2012cites this paper
• Aqueous Extract of Black Maca (Lepidium meyenii) on Memory Impairment Induced by Ovariectomy in Mice

  2011cites this paper
• CELLULAR AND MOLECULAR PHARMACOLOGY OF SIGMA RECEPTORS Review Article

  2011cites this paper
• Synthesis and in vitro evaluation of 7-methoxy-N-(pent-4-enyl)-1,2,3,4-tetrahydroacridin-9-amine-new tacrine derivate with cholinergic properties.

  2011cites this paper
• Prevention of scopolamine-induced memory deficits by schisandrin B, an antioxidant lignan from Schisandra chinensis in mice

  2011cites this paper
• Therapeutic applications of compounds in the Magnolia family.

  2011cites this paper
• Experimental research on nitric oxide and the therapy of Alzheimer disease: a challenging bridge.

  2011cites this paper
• Cholinesterase inhibitor use in Alzheimer's disease: the EPIFARM‐Elderly Project

  2011cites this paper
• Copy number variants in pharmacogenetic genes.

  2011cites this paper
• Tribuli fructus constituents protect against tacrine-induced cytotoxicity in HepG2 cells

  2010cites this paper
• Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2

  2010cites this paper
• Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease.

  2010cites this paper
• Substituted spiro [2.3'] oxindolespiro [3.2″]-5,6-dimethoxy-indane-1″-one-pyrrolidine analogue as inhibitors of acetylcholinesterase.

  2010cites this paper
• Ethical Issues in Pharmacogenetics

  2010cites this paper
• Disease progression meta‐analysis model in Alzheimer's disease

  2010cites this paper
• M1 and M4 muscarinic acetylcholine receptor regulation of neurotransmission and cell excitability in rodent hippocampus and prefrontal cortex.

  2010cites this paper
• Rôle des ADAM dans le processus physiopathologique de la maladie d'Alzheimer

  2010cites this paper
• Polymorphism of human cytochrome P450 enzymes and its clinical impact

  2009cites this paper
• Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development.

  2009cites this paper
• Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development.

  2009cites this paper
• High aryl acylamidase activity associated with cobra venom acetylcholinesterase: biological significance.

  2009cites this paper
• Protective effect of the ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activity

  2009cites this paper
• Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease

  2009cites this paper
• Aqueous extracts of FBD, a Chinese herb formula composed of Poria cocos, Atractylodes macrocephala, and Angelica sinensis reverse scopolamine induced memory deficit in ICR mice

  2009cites this paper
• Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease

  2009cites this paper
• Statistical and Data Mining Methodologies for Behavioral Analysis in Transgenic Mouse Models of Alzheimer's Disease: Parallels with Human AD Evaluation

  2009cites this paper
• Huprines for Alzheimer's disease drug development

  2008cites this paper
• Intranasal Mucoadhesive Microemulsion of Tacrine to Improve Brain Targeting

  2008cites this paper
• Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

  2008cites this paper
• The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis.

  2008cites this paper
• Why Do So Many Drugs for Alzheimer's Disease Fail in Development? Time for New Methods and New Practices?

  2008cites this paper
• Long-Term Treatment Response, Predictors and Biochemical Markers in Alzheimer's Disease

  2008influential citation
• Is Long-Term Treatment of Alzheimer’s Disease with Cholinesterase Inhibitor Therapy Justified?

  2007cites this paper
• Enzyme inhibition activities of Andrachne cardifolia Muell

  2007cites this paper
• Cognitive Predictors of Donepezil Therapy Response in Alzheimer Disease

  2007cites this paper
• Prescribing practice with cognition enhancers in outpatient care: are there differences regarding type of dementia?--Results of a representative survey in lower Saxony, Germany.

  2007cites this paper
• Re-evaluation of tacrine hepatotoxicity using gel entrapped hepatocytes.

  2007cites this paper
• Differential effect of tacrine and physostigmine on the secretion of the β-amyloid precursor protein in cell lines

  2007cites this paper
• Pharmacotherapy, clinical pharmacology and biomarker research in geriatric patients

  2007cites this paper
• Nose‐to‐brain delivery of tacrine

  2007cites this paper